Enhanced Influenza A H1N1 T-Cell Epitope Recognition and Cross-Reactivity to Protein-O-Mannosyltransferase 1 in Pandemrix-Associated Narcolepsy Type 1
Posted by Adam Awdish on
Pooled Human Serum, Heat Inactivated from Innovative Research was used in the following study:
A. Vuorela, T. L. Freitag, K. Leskinen, H. Pessa, T. Härkönen, I. Stracenski, T. Kirjavainen, P. Olsen, O. Saarenpää-Heikkilä, J. Ilonen, M. Knip, A. Vaheri, M. Partinen, P. Saavalainen, S. Meri & O. Vaarala
Nature Communications
April 16, 2021
Narcolepsy type 1 (NT1) is a chronic condition of the brain that causes patients to exhibit excessive daytime drowsiness, cataplexy, and disruption of nocturnal sleep patterns. NT1 is strongly associated with HLA-DQB1*0602, suggesting it may have an origin in the immune system. Since widespread distribution and use of the Pandemrix vaccine used to target the H1N1 Influenza A virus, there has been an increase in the number of adolescents diagnosed with NT1 after receiving the vaccine. In this study, researchers observed the T-Cell responses in patients that developed NT1 after receiving Pandemrix. Their results suggest that POMT1 could potentially act as an autoantigen that is recognized by T- and B-Cells in patients with NT1.
Related products available from Innovative Research also include:
Pooled Human AB Serum Plasma Derived Heat Inactivated